Pure Biologics stock reports a 33.60 percent August gain

Published on 09/30/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pure Biologics stock posted a 33.60 percent August gain as the issuer became MultiQure on August 4, 2026. Q1 2026 revenue was PLN 0.00 and EBITDA was PLN -1.70 million.

Pure Biologics, PLPURE000013, Illustration mit AI erstellt.

Pure Biologics (ISIN PLPURE000013) stock posted a 33.60 percent gain in August 2026 as the issuer moved through a legal and strategic transformation. StockWatch reported that the name change and capital increase were registered on August 4, 2026.

A new name and ticker

The former Pure Biologics entity now operates as MultiQure, with the change tied to a new shareholder structure and a revised business direction. According to Parkiet on August 31, 2026, the Warsaw exchange also changed the ticker after the corporate changes.

The new ownership gives the transformation a measurable capital-market dimension. StockWatch reported that Biofund Capital Management held 49.99 percent of voting rights, compared with 14.99 percent for JD Copilot. Biofund's stake was more than triple JD Copilot's position.

Q1 figures show the funding test

MultiQure's Q1 2026 figures show a development-stage company still operating before meaningful revenue generation. The company reported PLN 0.00 in revenue, EBITDA of PLN -1.70 million and a net loss of PLN -2.24 million for Q1 2026, according to stockd on September 16, 2026.

Those figures place financing and execution at the center of the investment case. The August share gain therefore followed corporate restructuring and ownership changes rather than a reported revenue acceleration.

GPW listing keeps the old link

Pure Biologics remains identifiable through its biotechnology roots and its Polish listing. A company profile from 6ix identifies the former issuer as listed on GPW under PUR and classifies it in Health Technology and Biotechnology. The same source describes the business as focused on innovative biopharmaceuticals and therapies.

Restructuring now defines the story

For investors, the central comparison is between the 33.60 percent August gain and the PLN 0.00 revenue reported for Q1 2026. The stock performance reflects a sharp market response to the new corporate structure, while the financial statements still show the distance to commercial scale.